Destiny's XF drug series represents a totally new antimicrobial platform. With a novel structure and a unique mechanism of action, the likelihood of resistance developing is very remote.

Initial applications address the prevention and treatment of multidrug-resistant bacteria, but an extended programme of research is designed to uncover numerous additional clinical applications in infectious disease.